Zacks Research upgraded Eli Lilly and Company (LLY) on January 3, 2026. The rating moved from "hold" to a "strong-buy." This improved rating reflects a positive outlook on the company’s financial prospects. Lilly maintains a leading position in high-growth pharmaceutical markets, specifically diabetes and obesity treatments.
The upgrade precedes an anticipated eventful year for the company. Investors are watching for several 2026 catalysts, including a key FDA approval decision for the oral weight-loss candidate orforglipron. Further clinical trial data for the next-generation therapy, retatrutide, is also expected. These pipeline developments are crucial for sustaining Lilly's growth trajectory.
The announcement occurred over the weekend, resulting in no immediate market reaction. The consensus among analysts remains a "Buy." The new rating from Zacks reinforces the existing bullish sentiment surrounding the stock's performance potential.